Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235054 | 1.00 | PKM (0.57) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL3235046 | 1.00 | PKM (0.57) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL12169319 | 0.91 | AKR1C3 (0.62) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL2446490 | 0.90 | PKM (0.66) | PKMALDH1A1POLBHTTTSHR | |
| SCHEMBL4940237 | 0.90 | ALDH1A1 (0.64) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL10361037 | 0.87 | AKR1C3 (0.58) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL19011448 | 0.86 | PKM (0.59) | PKMALDH1A1NPC1RAB9APOLB | |
| SCHEMBL9535608 | 0.86 | LMNA (0.60) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL10548617 | 0.86 | PKM (0.56) | PKMALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL16777043 | 0.84 | AKR1C3 (0.51) | ALDH1A1HTTTSHRLMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024099337-A1 | THIADIAZOLYL DERIVATIVES, COMPOSITIONS, AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-16 | — | — | WO | disclosed |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | MERLI VALERIANO | 2009-06-18 | — | — | US | disclosed |
| WO-2009006413-A1 | SUBSTITUTED PYRROLIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-10-30 | — | — | US | disclosed |
| US-7442806-B2 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-10-28 | — | — | US | disclosed |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS U.S.A. INC. FOR BARBADOS | 2008-09-11 | — | — | US | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICALS USA, INC. FOR BARBADOS | 2008-09-04 | — | — | US | disclosed |
| EP-1891034-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-02-27 | — | — | EP | disclosed |
| EP-1877393-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-01-16 | — | — | EP | disclosed |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-30 | — | — | US | disclosed |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007076157-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICALS INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007076158-A2 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214835-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
| US-20070203221-A1 | (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-diphenylacetamide, selective muscarinic acetylcholine receptor antagonists, used for treating urogenital disorders such as incontinence | CHRNE, CHRM3, CHRM2 | PKM 2832/4885ALDH1A1 424/4885KDM4E 3414/4885 |
| US-20080221338-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
| US-20080269503-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
| US-20070197631-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
| US-20080269505-A1 | Processes for preparing darifenacin hydrobromide | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
| US-20090156831-A1 | PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE | OPRL1, AVPR2, AVPR1B | PKM 4425/4885ALDH1A1 1853/4885KDM4E 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.